Table of Contents Author Guidelines Submit a Manuscript
Stroke Research and Treatment
Volume 2011 (2011), Article ID 721613, 5 pages
http://dx.doi.org/10.4061/2011/721613
Research Article

Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

1Shaheed Beheshti University of Medical Sciences and Health Services, Tehran 19839-63113, Iran
2Department of Neurology, Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran 13336-31151, Iran
3Tehran University of Medical Sciences and Health Services, Tehran, Iran
4Gylan University of Medical Sciences and Health Services, Gylan, Iran
5Milad Hospital, Tehran, Iran
6Social Security, Tehran, Iran
7Azad University of Medical Sciences, Tehran 19168, Iran

Received 7 October 2010; Revised 22 February 2011; Accepted 26 April 2011

Academic Editor: Daniel Bereczki

Copyright © 2011 A. A. Harandi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months. Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline ( ). Repeated measures analysis showed that Fugl-Meyer assessment was significantly higher in the treatment group during 12 weeks after stroke ( ). Good tolerability to treatment was shown, and adverse events were mild and transient. Conclusion. MLC601 showed better motor recovery than placebo and was safe on top of standard ischemic stroke medications especially in the severe and moderate cases.